Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 59-7939 dose-finding study in acute symptomatic deep-vein thrombosis
ACTRN12605000597695Phase 2Completed
- Sponsor
- Bayer
- Start
- Dec 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of rivaroxaban in deep vein thrombosis (DVT) (4 arms), sponsored by Bayer. Primary endpoints: Symptomatic recurrent deep-vein thrombosis or symptomatic fatal or non-fatal pulmonary embolism, Deterioration of thrombotic burden on imaging and 1 more. Started Dec 2004; status: completed.
02
Drugs
rivaroxaban
03
Conditions
deep vein thrombosis (DVT)
Beyond the preview
Go deeper on ACTRN12605000597695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000597695.